Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab-rezetecan vs Trastuzumab Deruxtecan in Neoadjuvant HER2+ Breast Cancer
NCT07416253Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Henan Cancer Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07416253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416253.